American Doctors Online (ADOL) 10-K 9 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	American Doctors Online, Inc.
Entity Central Index Key	1164191
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$0
Entity Common Stock, Shares Outstanding		12,172,409
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$49,898	$96,782
Accounts receivable	103,602	115,917
Prepaid assets		12,500
Total current assets	153,500	225,199
Patents Pending	122,889	102,128
Patents, net of accumulated amortization of $38,779 (2014) and $33,290 (2013)	48,818	52,707
Furniture, fixtures and equipment, net of accumulated depreciation of $186,622 (2014) and $168,140 (2013)	19,775	38,257
Total assets	344,982	418,291
Current Liabilities:
Accounts payable and accrued expenses	607,221	308,944
Accounts payable and accrued expenses, related parties	297,411	21,610
Series B convertible preferred stock obligation	179,667
Deferred rent	52,924
Total current liabilities	1,137,223	330,554
Convertible notes payable, stockholder	119,055	104,055
Total liabilities	1,256,278	434,609
Commitment and Contingencies (Note 9)
Deficit:
Preferred stock, $0.01 par value; 15,000,000 shares authorized, Series A Convertible Preferred Stock, $0.01 par value; 3,500,000 shares authorized; 3,500,000 shares issued and outstanding (2014)	35,000	35,000
Common stock, $0.01 par value; 100,000,000 shares authorized; 12,192,408 (2014) and 11,261,175 (2013) shares issued and outstanding	121,923	112,611
Deferred equity compensation		-216,981
Additional paid-in capital	17,408,041	16,842,107
Accumulated deficit	-16,064,010	-14,333,703
Total company stockholders' equity	1,500,954	2,439,034
Less noncontrolling interest	-2,412,250	-2,455,352
Total deficit	-911,296	-16,318
Total Liabilities and Stockholders' Deficit	$344,982	$418,291

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accumulated amortization of patents	$38,779	$33,290
Accumulated depreciation of furniture, fixtures and equipment	$186,622	$168,140
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	3,500,000	3,500,000
Preferred stock, shares outstanding	3,500,000	3,500,000
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	12,192,408	11,261,175
Common stock, shares outstanding	12,192,408	11,261,175
Series A Convertible Preferred Stock
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	3,500,000	3,500,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Fee revenue, net	$496,446	$425,918
Operating expenses:
Salaries and management fees (including stock compensation expenses of $792,227 (2014) and $4,105,546 (2013)	1,230,194	4,324,401
Rent and occupancy costs	48,410	23,758
Travel and entertainment	32,412	26,918
Professional and consulting fees	650,753	606,772
Insurance	55,251	49,890
Depreciation and amortization	23,971	30,224
Other general and administrative	86,457	81,697
Total operating expenses	2,127,448	5,143,660
Operating loss	-1,631,002	-4,717,742
Other Expense:
Interest expense	-50,972	-1,865
Interest expense, stockholder	-5,231	-5,343
Total other expense	-56,203	-7,208
Net loss	-1,687,205	-4,724,950
Less net income (loss) attributable to noncontrolling interest	43,102	-134,318
Net loss attributable to American Doctors Online, Inc.	($1,730,307)	($4,590,632)
Basic and diluted loss attributable to American Doctors Online, Inc. common stockholders, per share	($0.15)	($0.54)
Weighted average number of common shares outstanding Basic and diluted	11,751,840	8,558,134

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Stock compensation expense included in salaries and management fees	$792,227	$4,105,546

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Common Stock	Series A Convertible Preferred Stock	Deferred Equity Compensation	Additional Paid-In Capital	Noncontrolling Interest	Accumulated Deficit	Total
Beginning balance, amount at Dec. 31, 2012	$64,654			$12,163,617	($2,321,034)	($9,743,071)	$164,116
Beginning balance, shares at Dec. 31, 2012	6,465,371
Common stock issued for cash, shares	740,000
Common stock issued for cash, amount	7,400			362,600			370,000
Preferred stock issued for patent assignment, shares		3,500,000
Preferred stock issued for patent assignment, amount		35,000		3,465,000			3,500,000
Common stock issued for accounts payable, shares	104,500
Common stock issued for accounts payable, amount	1,045			51,200			52,245
Common stock issued for services and deferred compensation, shares	1,129,671
Common stock issued for services and deferred compensation, amount	11,297		-216,981	553,539			347,855
Common stock issued for cancellation of stock options, shares	2,821,633
Common stock issued for cancellation of stock options, amount	28,216			-28,216
Stock based compensation				274,367			274,367
Net income (loss)					-134,318	-4,590,632	-4,724,950
Ending balance, amount at Dec. 31, 2013	112,611	35,000	-216,981	16,842,107	-2,455,352	-14,333,703	-16,318
Ending balance, shares at Dec. 31, 2013	11,261,175	3,500,000
Common stock issued for services, shares	20,000
Common stock issued for services, amount	200			9,800			10,000
Common stock issued for consulting services, shares	911,233
Common stock issued for consulting services, amount	9,112			446,505			455,617
Stock based compensation				109,629			109,629
Deferred stock compensation			216,981				216,981
Net income (loss)					43,102	-1,730,307	-1,687,205
Ending balance, amount at Dec. 31, 2014	$121,923	$35,000		$17,408,041	($2,412,250)	($16,064,010)	($911,296)
Ending balance, shares at Dec. 31, 2014	12,192,408	3,500,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($1,687,205)	($4,724,950)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23,971	30,224
Non cash interest expense Series B Convertible Preferred Stock	44,917
Stock based compensation	792,227	4,105,546
Change in operating assets and liabilities:
Decrease (increase) in prepaid expenses	12,500	-12,500
Decrease (increase) in accounts receivable	12,315	-61,491
Increase in deferred rent	52,924
Increase in accounts payable and accrued expenses	676,579	289,509
Net cash used in operating activities	-71,772	-373,662
Cash flows from investing activities:
Payment of patent pending costs	-20,761	-7,690
Payment of patent costs	-1,600	-5,036
Net cash used in investing activities	-22,361	-12,726
Cash flows from financing activities:
Proceeds from sale of common stock		370,000
Proceeds from issuance of convertible notes, related party	15,000	105,055
Repayments on convertible notes, related party		-1,000
Proceeds from sale of Series B Preferred Stock	32,250
Net cash provided by financing activities	47,250	474,055
Net (decrease) increase in cash and cash equivalents	-46,883	87,667
Cash and cash equivalents, beginning	96,782	9,114
Cash and cash equivalents, ending	49,898	96,782
Supplemental disclosure of cash flow information:
Cash paid for interest	2,475
Cash paid for income taxes
Schedule of non-cash investing and financing activities:
Issuance of common stock for accounts payable, related parties		52,245
Issuance of preferred stock for assignment of patents and patents pending		16,675
Settlement of accrued expenses with issuance of preferred stock	$136,667

Organization

Organization	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Note 1 - Organization
	Business
	American Doctors Online, Inc. (the “Company” or “ADOL”) was formed in the State of Delaware on September 17, 1999. ADOL owns four U.S. patents and has three pending patent applications. These patents cover the essential core processes required for the delivery of telehealth and telemedicine services. The Company’s business model is to license to telehealth and/or telemedicine providers one or more of the Company’s patents pursuant to non-exclusive agreements with terms and conditions similar to other licensing agreements involving medical related Intellectual property. The Company believes its’ intellectual property includes the fundamental methodologies inherent to the provision of telehealth and/or telemedicine.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies
	Basis of Presentation and Principles of Consolidation
	The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America. The consolidated financial statements of the Company include the Company and PDRx. All material inter-company balances and transactions have been eliminated.
	ADOL receives fees pursuant to a Management Services and License Agreement with PhoneDOCTORx, LLC, (“PDRx”). PDRx, is a Massachusetts limited liability company, owned by five physicians, who collectively own over 70% of ADOL. Based on the common control and ownership of ADOL and PDRx, PDRx is considered a variable interest entity, of which ADOL is the primary beneficiary. Accordingly, these consolidated financial statements include the accounts of PDRx. ADOL exerts no influence on, or has any involvement in the practice of medicine by PDRx’s clinical staff.
	Variable Interest Entity
	The Company determined that it was the primary beneficiary of PDRx based primarily on qualitative factors. Specifically, PDRx was formed at the direction of the Company. PDRx is managed and effectively controlled, other than related to the provision of medical services, by the Company through common ownership, and a substantial portion of PDRx revenues accrue to the Company in the form of management fees. The carrying value of the assets and liabilities of PDRx included in the accompanying consolidated balance sheets as of December 31, 2014 and December 31, 2013 are as follows:
			2014			2013
	Cash		$	9,977		$	73,234
	Accounts receivable			89,252			107,778
	Total current assets			99,229			181,012
	Property and equipment, net			825			1,523
	Total assets		$	100,054		$	182,535
	Accounts payable and accrued liabilities		$	441,424		$	176,567
	Due to related party			78,800			24,800
	Total current liabilities		$	520,224		$	201,367
	Emerging Growth Company
	We qualify as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, we can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include the valuation of stock-based compensation, the allowance for doubtful accounts and impairment of patents.
	Fair Value of Financial Instruments
	The carrying value of the Company’s accounts receivable and accounts payable and accrued expenses approximate fair value due to their short term nature. The carrying value of convertible notes payable, stockholder approximates fair value because the terms are similar to prevailing market rates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents.
	Accounts Receivable
	Pursuant to licenses entered into by PDRx and their customers, the Company bills the customer monthly and records the corresponding accounts receivable due from its licensees. The Company extends credit of up to forty five (45) days from invoice date. The Company provides allowance for losses through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability of the principal is unlikely. The allowance is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience. While management uses the best information available to make its evaluations, this estimate is susceptible to significant change in the near term. The Company has not recorded an allowance for losses as of December 31, 2014 and 2013, as management deemed all accounts receivable to be collectible.
	Patents
	The Company capitalizes legal fees and filing costs associated with the development and filing of its patents. Patents are generally amortized over an estimated useful life of 17 years using the straight-line method beginning on the issue date. Amortization expense of $5,489 and $5,452 was recorded during the years ended December 31, 2014 and 2013, respectively.
	Property and Equipment
	Property and equipment are stated at cost, and depreciation is provided by use of straight-line methods over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows:
	Office equipment and furniture	5 years
	Computer hardware and software	3 years
	The Company's property and equipment consisted of the following at December 31, 2014 and December 31, 2013:
			2014			2013
	Furniture and Equipment		$	191,597		$	191,597
	Software			14,800			14,800
	Accumulated depreciation			(186,622	)		(168,140	)
	Balance		$	19,775		$	38,257
	Depreciation expense of $18,482 and $24,772 was recorded for the years ended December 31, 2014 and 2013, respectively.
	Revenue Recognition
	The Company recognizes revenue in accordance with FASB ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria are met (1) persuasive evidence of an arrangement exists, (2) delivery of products and services has occurred, (3) the fee is fixed or determinable and (4) collectability is reasonably assured.
	The Company recognizes revenue during the period in which the licensed products are utilized. PDRx, through the sub-licensing of the ADOL patents, provides remote covering physician consultations via audio and/or video conferencing technologies. It provides Extended Care Facilities (“ECF”), ECF nurses, patients and their families’ confidential, real-time access to Board Certified physicians in non-urgent, urgent and emergent care settings through a state-of-the-art medical call center. PDRx through sub-licenses of ADOL’s patented telehealth / telemedicine technology provides medical services including face-to-face, real-time access to covering physicians, resulting in reduction of unnecessary and avoidable transfers and readmissions to the Emergency Department.
	Advertising
	The Company records advertising costs as incurred. For the years ended December 31, 2014 and 2013, advertising expense, included in general and administrative expense, was $1,963 and $5,231, respectively.
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. The Company records a valuation allowance related to a deferred tax asset when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.
	ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest and penalties as a component of interest and other expenses. To date, the Company has not been assessed, nor has the Company paid, any interest or penalties.
	The Company measures and records uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized. The Company’s tax years subsequent to 2005 remain subject to examination by federal and state tax jurisdictions.
	Earnings (Loss) Per Share
	The Company reports earnings (loss) per share in accordance with ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing net income (loss), after deducting preferred stock dividends accumulated during the period, by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. The following potentially dilutive securities for the years ended December 31, 2014 and 2013 were not included in the calculation of diluted loss per share because their impact was anti-dilutive.
			December 31,
			2014			2013
	2007 Option Plan			515,000			515,000
	2011 Option Plan			3,747,360			4,047,137
	Class A Preferred Stock			7,000,000			—
	Class B Preferred Stock			93,333			—
	Convertible Notes			119,055			104,055
				11,474,748			4,666,192
	Accounting for Stock-based Compensation
	The Company accounts for stock based compensation in accordance with ASC 718, Compensation - Stock Compensation (“ASC 718”).  ASC 718 establishes accounting for stock-based awards exchanged for employee services.  Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant).  The fair value of our common stock options are estimated using the Black Scholes option-pricing model.
	The Company estimates the fair value of stock options and warrants using the Black-Scholes option-pricing model, which was developed for use in estimating the fair value of options that have no vesting restrictions and are fully transferable. This model requires the input of subjective assumptions, including the expected price volatility of the underlying stock and the expected life of stock options. Projected data related to the expected volatility of stock options is based on the average volatility of the trading prices of comparable companies and the expected life of stock options is based upon the term and vesting schedules of the options. Changes in these subjective assumptions can materially affect the fair value of the estimate, and therefore the existing valuation models do not provide a precise measure of the fair value of our stock options and warrants. The expected dividend rate is zero as the Company does not expect to pay or declare any cash dividends on common stock. The risk-free rates for the expected terms of the stock options are based on the U.S. Treasury yield curve in effect at the time of the grant.
	The Company accounts for stock awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. The measurement date is the earlier of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete.
	The Company estimates the fair value of shares of common stock issued for services based on the price of shares of the Company’s common stock sold in contemporaneous private placements of offerings on the date shares are granted.
	Recent Accounting Pronouncements
	Recent accounting pronouncements issued by the FASB and the SEC did not have, or are not believed by management to have, a material impact on the Company's present or future consolidated financial statements.

Patents

Patents	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Patents	Note 3 – Patents
	Patents as of December 31, 2014 consist of the following:
	Gross carrying amount		$	87,597
	Accumulated amortization			(38,779	)
	Net carrying amount		$	48,818
	A reconciliation as December 31, 2014, of the net carrying amount of the Company’s Patent Rights is as follows:
	Balance – December 31, 2013		$	52,707
	Patent maintenance costs			1,600
	Amortization			(5,489	)
	Balance – December 31, 2014		$	48,818
	As of December 31, 2014, Patent Rights are expected to be amortized over the remaining lives as follows:
		Twelve Months Ending December 31,
		2015				4,472
		2016				4,472
		2017				4,472
		2018				4,472
		2019				4,472
		Thereafter				26,458
					$	48,818

Sales_Concentration_and_Concen

Sales Concentration and Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Sales Concentration and Concentration of Credit Risk	Note 4 – Sales Concentration and Concentration of Credit Risk
	Cash
	Financial   instruments   that   potentially   subject   the   Company to concentrations of credit risk consist principally of cash. The Company maintains cash balances at one financial institution, which is insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company has not experienced any losses in such accounts.
	Sales and Accounts Receivable
	Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the years ended December 31, 2014 and 2013 and the accounts receivable balance as of December 31, 2014:
		Customer	Sales % Year			Sales % Year			Accounts Receivable
			Ended			Ended			Balance as of
			31-Dec-13			31-Dec-14			31-Dec-14
		A		29.1	%		39.3	%	$	33,872
		B		27.9	%		31.3	%	$	27,742
		C		14.9	%		—		$	—
		D		11	%		—		$	—

Convertible_Notes_Payable_Stoc

Convertible Notes Payable, Stockholder	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Convertible Notes Payable, Stockholder	Note 5 – Convertible Notes Payable, Stockholder
	During the year ended December 31, 2013, the Company issued six convertible promissory notes to its Chairman, Dr. Bulat (the “Bulat Notes”) for $105,055 in the aggregate and the Company repaid $1,000. During the year ended December 31, 2014, the Company issued two additional promissory notes to Dr. Bulat for $15,000 in the aggregate. As of December 31, 2014, the balance of the Bulat Notes was $119,055. The notes mature on the third anniversary of their issuance (the “Maturity Date”) and carry a per annum interest rate of 5%. The Notes automatically convert on the nine month anniversary following the effectiveness of the Company becoming a public company (the “Conversion Date”) at a conversion price equal to the average closing bid price over the five consecutive days immediately preceding the Conversion Date.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions
	For the years ended December 31, 2014 and 2013, the Company incurred rent expense of $35,281 and $9,558, respectively, on behalf of St. Luke’s Emergency Associates (“SLEA”). Dr. Paul Bulat, the Company’s founder and Chairman is the President of SLEA.
	For the years ended December 31, 2014 and 2013, the Company recorded interest expense, stockholder of $5,231 and $5,343, respectively. As of December 31, 2014, accrued interest of $10,574 is owed to the stockholder and is included in accounts payable and accrued expenses, related parties.
	In June 2013, the Company issued 2,000,000 shares of common stock to Mr. Lane, our Chief Executive Officer and President (resigned October 2014) and cancelled fully vested options to purchase 2,000,000 shares of common stock. The Company compared the fair value of the options cancelled and the common stock awarded and determined that no additional compensation was required to be recognized because the fair value of the common stock issued did not exceed the fair value of the cancelled options immediately prior to the cancellation and award.
	Effective June 1, 2013, the Company entered into a consulting agreement with Venture Equity, LLC and agreed to compensate Venture Equity $5,000 per month and to issue 347,169 shares of common stock. The Company valued the shares at $0.50 per share and accordingly, $173,585 is included in stock compensation expense for the year ended December 31, 2013.
	Effective on November 1, 2013 (the “Effective date”), the Company appointed Mr. Hollander as the Chief Financial Officer of the Company, and agreed to issue Mr. Hollander or his assigns 520,754 additional shares of common stock of the Company, and increased the monthly compensation to $8,000. Pursuant to this appointment, Mr. Hollander earned 50% of the additional shares on the nine month anniversary of the Effective Date and earned 50% on the one year anniversary of the Effective Date. Accordingly, the 520,754 shares of common stock, with a value of $260,377 were initially recorded as deferred equity compensation. The Company valued the common stock at $0.50 per share, the same value as the then most recent sales of common stock. The Company amortized the deferred equity compensation over the twelve month term, and has included $216,981 and $43,395, respectively, in stock compensation expense for the years ended December 31, 2014 and 2013. As of December 31, 2014, the balance owed Mr. Hollander related to the monthly compensation is $21,000 and is included in accounts payable and accrued expenses related parties.
	The Board also agreed to enter into an employment agreement with Mr. Bulat (Chief Innovations Officer) for an annual salary up to $300,000 effective January 1, 2014. The Company and Mr. Bulat agreed to accrue $10,000 per month for the year ended December 31, 2014 and agreed to increase the annual compensation to the full amount at a later date. Included in salaries and management fees for the year ended December 31, 2014 is $120,000, included in accounts payable and accrued expenses related party.
	On October 27, 2014, Mr. Brian Lane (“Lane”) resigned as CEO of the Company. Mr. Lane remains a member of the Board of Directors of the Company. On October 29, 2014, the Company and Mr. Lane entered into a Resignation and Separation Agreement (the “RSA”). Pursuant to the RSA, the Company has agreed to provide consideration to Mr. Lane of $58,856 in fourteen bi-weekly payments of approximately $4,204. The consideration included wages accrued and unpaid as of October 24, 2014. Mr. Lane’s resignation was not due to any disagreement with the Company, the Board or the Company’s management. Included in salaries and management fees for the years ended December 31, 2014 and 2013, is $148,315 and $127,954, respectively. As of December 31, 2014, the balance owed Mr. Lane is $37,837 for unpaid salary and severance and is included in accounts payable and accrued expenses related parties.
	On October 23, 2013, the Company executed a Patent Purchase Agreement with Mr. Bulat. Pursuant to the Patent Purchase Agreement, the Company issued 3,500,000 shares of Series A Convertible Preferred Stock. The Company recorded an expense of $3,483,325 for the year ended December 31, 2013, and has included $16,675 (the inventor’s historical cost basis) in patents pending on the balance sheet presented herein. The amounts were based on the conversion feature of the Series A Preferred Stock, whereby the holder, in his sole discretion is entitled to convert the 3,500,000 shares of Series A Preferred Stock to 7,000,000 shares of Company common stock. The Company valued the common stock at $0.50 per share, the same value as the most recent sales of common stock.
	During the year ended December 31, 2013, the Company issued six convertible promissory notes to Dr. Bulat (the “Bulat Notes”) for $105,055 in the aggregate. During the year ended December 31, 2013, the Company repaid $1,000 of the Bulat Notes (see Note 5). During the year ended December 31, 2014, the Company issued two additional promissory notes to Dr. Bulat for $15,000 in the aggregate. The Company recorded interest expense, stockholder of $5,231 and $5,343 for the years ended December 31, 2014 and December 31, 2013, respectively. As of December 31, 2014, $10,574 is included in accounts payable and accrued expenses, related party on the December 31, 2014, balance sheet.
	As of December 31, 2014, the Company owes its Chief Technology Officer $108,000 for accrued and unpaid fees and is included in accounts payable and accrued expenses, related parties.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	Note 7 – Stockholders’ Deficit
	Deferred Equity Compensation
	During the year ended December 31, 2013, the Company’s CFO was issued 520,754 shares of common stock. The common stock was valued at $260,377, equal to $0.50 per share, the same value as the most recent sales of common stock. The Company amortized the deferred equity compensation over the twelve month term, and has included $216,981 and $43,395, respectively, in stock compensation expense for the years ended December 31, 2014 and 2013.
	Common Stock
	On June 7, 2013, the Company amended its’ Articles of Incorporation to increase the number of authorized shares to 17,500,000 of common stock, par value $.01 per share.
	On June 20, 2013, the Company amended its’ Articles of Incorporation to increase the number of authorized shares to 100,000,000 consisting of 95,000,000 shares of common stock, par value $0.01 per share and 5,000,000 shares of preferred stock. The preferred stock may be created in any number of series and issued from time to time, with such designations, preferences, rights and restrictions as shall be stated in resolutions adopted by the Board of Directors.
	On June 30, 2013, the Company issued 11,748 shares of common stock for services. The Company recorded an expense of $5,874 for the issuance, based on a per share price in recent private placements of $0.50 per share. Also on June 30, 2013 the Company issued 4,500 shares of common stock in payment of accounts payable of $2,250. The shares were issued at $0.50 per share.
	From July 2013 to September 2013, pursuant to a Private Placement Memorandum (“PPM”) the Company sold 740,000 shares of common stock for $0.50 per share for gross proceeds of $370,000.
	On September 30, 2013, the Company issued 100,000 shares of common stock in settlement of accrued and unpaid legal fees of $49,995. The shares were issued at $0.50 per share.
	On October 7, 2013, the Company issued 867,923 shares of common stock to Venture Equity for the services of Mr. Barry Hollander as CFO of the Company (see note 6).
	On November 18, 2013, the Company amended its Articles of Incorporation to increase the number of authorized shares to 115,000,000 consisting of 100,000,000 shares of common stock, par value $0.01 per share and 15,000,000 shares of preferred stock, par value $0.01 per share.
	On June 18, 2014, pursuant to a consulting agreement, the Company issued 911,233 shares of common stock to Makena (see note 9). During the year ended December 31, 2014, the Company recorded an expense of $455,617 for the issuance, based on a per share price in the most recent private placements of $0.50 per share.
	On December 12, 2014, the Company issued 10,000 shares of common stock in satisfaction of consulting services provided. During the year ended December 31, 2014, the Company recorded an expense of $5,000 for the issuance, based on a per share price in the most recent private placements of $0.50 per share.
	Also on December 12, 2014, the Company issued 10,000 shares of common stock to two employees in recognition for services performed in the past. Each received 5,000 shares of common stock under the Company’s 2011 Stock Option/Issuance Plan. The Company recorded an expense of $5,000 for the issuance, based on a per share price in the most recent private placements of $0.50 per share.
	Series A Preferred Stock
	On October 7, 2013, the Board of Directors of the Company authorized the filing of a Certificate of Designation establishing Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and authorized 3,500,000 shares be available for issuance. Each share of Series A Preferred Stock shall be convertible at the option of the Holder thereof and without the payment of additional consideration by the Holder thereof, at any time, into shares of Common Stock at a conversion rate of two (2) shares of Common Stock for every one (1) share of Series A Preferred Stock and holders of Series A Preferred Stock shall have the right to cast fifteen (15) votes for each share held of record on all matters submitted to a vote of holders of the Corporation’s common stock, including the election of directors, and all other matters as required by law. The holders of Series A Preferred Stock shall vote together with all other classes and series of common stock of the Corporation as a single class on all actions to be taken by the common stock holders of the Corporation except to the extent that voting as a separate class or series is required by law.
	On October 23, 2013, the Company executed a Patent Purchase Agreement with Mr. Bulat. Pursuant to the Patent Purchase Agreement, the Company issued 3,500,000 shares of Series A Preferred Stock. The Company recorded an expense of $3,483,325 for the year ended December 31, 2013, and has included $16,675 (the inventor’s cost basis) in patents pending on the consolidated balance sheet presented herein. The amounts were based on the conversion feature of the Series A Preferred Stock, whereby the holder, in his sole discretion is entitled to convert the 3,500,000 shares of Series A Preferred Stock to 7,000,000 shares of Company common stock. The Company valued the common stock at $0.50 per share, the same value as the most recent sales of common stock.
	Series B Preferred Stock
	On November 13, 2013, the Board of Directors of the Company authorized the Company to sell 4,000,000 shares of Series B Convertible Redeemable Preferred Stock (the “Series B Preferred Stock”), at $0.75 per share.
	On April 3, 2014, the Company received proceeds of $26,250 from the sale of 35,000 shares of Series B Preferred Stock. The shares were issued at $0.75 per share.
	On July 2, 2014, the Company received proceeds of $6,000 from the sale of 8,000 shares of Series B Preferred Stock. The shares were issued at $0.75 per share.
	On August 18, 2014, the Company issued 136,667 shares of Series B Preferred Stock in satisfaction of $102,500 of accrued and unpaid consulting fees. The shares were issued at $0.75 per share.
	The Series B Preferred Stock and any accrued and unpaid dividends thereon shall, with respect to rights on liquidation, winding up and dissolution, rank senior to the common stock, and the Series A Preferred Stock.
	The holders of shares of Series B Preferred Stock are entitled to receive an annual dividend at the rate of eight percent (8%) per annum. Such dividend can be paid in cash or in the issuance of additional Series B Preferred Shares.
	Each share of Series B Preferred Stock shall automatically convert (the “Mandatory Conversion”) and without the payment of additional consideration by the Holder thereof, into shares of Common Stock on the Mandatory Conversion Date (as hereinafter defined) at a conversion rate of seventy-five percent (75%) of the price of the Common Stock sold for cash in a non-affiliated equity transaction (the “Equity Price”). The Mandatory Conversion Date shall be the date that the five (5) day weighted average trading price of the Common Stock exceeds 110% of the Equity Price.
	At any time, or upon receipt of a redemption notice by the Company, the Holder will have twenty (20) days to elect to convert the Series B Preferred Stock into Common Stock at a price per share equal to a twenty-five percent (25%) discount to the most recent Common Stock price per share paid by any non-affiliated investor in a subsequent financing to the Series B Preferred Stock.
	Because the Series B convertible preferred stock is convertible into a variable number of shares of the Company’s stock, determined with referenced to a fixed dollar amount, the fair value of the conversion option, which approximates its intrinsic value, is required to be presented as a liability. Accordingly, $179,667 is presented as Series B convertible preferred stock obligation, a liability on the accompanying consolidated balance sheets as of December 31, 2014. The excess of the fair value of the conversion option over the proceeds received was recorded as interest expense of $44,917 for the year ended December 31, 2014.
	Stock Options
	During the year ended December 31, 2007, the Company adopted the 2007 Stock Option/Stock Issuance Plan (the “2007 Plan”). The 2007 Plan permits the grants of Options to purchase shares of Common Stock, either ISOs or Non-Qualified Options; and awards of Restricted Stock. The Board shall have the right to grant other Awards based upon the Common Stock having such terms and conditions as the Board may determine, including, without limitation, the grant of shares based upon certain conditions, the grant of securities convertible into Common Stock and the grant of stock appreciation rights, phantom stock awards or stock units.
	Effective May 17, 2011, the Company adopted the 2011 Stock Option/Stock Issuance Plan (the “2011 Plan”). The 2011 Plan permits the grants of Options to purchase shares of Common Stock, either ISOs or Non-Qualified Options; and awards of Restricted Stock. The Board shall have the right to grant other Awards based upon the Common Stock having such terms and conditions as the Board may determine, including, without limitation, the grant of shares based upon certain conditions, the grant of securities convertible into Common Stock and the grant of stock appreciation rights, phantom stock awards or stock units.
	A summary of the plans as of December 31, 2014 is as follows:
	Plan	Authorized	Granted	Available
	2007	1,500,000	515,000	985,000
	2011	10,000,000	3,747,360	6,252,460
	A summary of the activity of options for the years ended December 31, 2014 and 2013 is as follows:
			Options			Weighted-		Weighted-		Weighted-
						Average		Average		Average remaining term
						exercise		grant date
						price		fair value
	Balance January 1, 2013			10,746,903		$	1.28
	Options granted			171,561		$	1.25	$	1.11
	Options cancelled			(6,356,327	)	$	1.27
	Outstanding as of December 31, 2013			4,562,137		$	1.28			6.75
	Options expired			(299,777	)
	Outstanding as of December 31, 2014			4,262,360		$	1.28			6.22
	Exercisable at December 31, 2014			4,251,185		$	1.28			6.22
	As of December 31, 2014, there are options to purchase 11,661 shares of common stock that have not vested. Upon their vesting, expecting to occur through December 31, 2015, the Company will realize future expenses of $13,498.
	The fair value for the options granted during the years ended December 31, 2014 and 2013 were estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted average assumptions:
			2013
	Expected volatility			81	%
	Expected dividend yield			0	%
	Expected life (in years)			4
	Risk free interest rate			0.7	%
	During the years ended December 31, 2014 and 2013, the Company recorded stock based compensation expense related to stock options of $109,629 and $274,367 respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 – Income Taxes
	Deferred income taxes reflect the net tax effects of operating loss and tax credit carry forwards and temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Due to the uncertainty of the Company’s ability to realize the benefit of the deferred tax assets, the deferred tax assets are fully offset by a valuation allowance at December 31, 2014, and December 31, 2013.
	Income tax expense for 2014 and 2013 is as follows:
		2014			2013
	Current:
	Federal	$	—		$	—
	State		—			—
			—			—
	Deferred:
	Federal		(304,501	)		(210,597	)
	State		(50,208	)		(34,749	)
	Change in Valuation allowance					245,346
		$	—		$	—
	The following is a summary of the Company’s deferred tax assets at December 31, 2014 and 2013:
		2014			2013
	Deferred Tax Assets:
	Net operating losses	$	481,599		$	364,842
	Accounts payable		379,013			151,625
	Net deferred tax assets		860,612			516,467
	Deferred Tax Liabilities:
	Accounts receivable		(45,727	)		(46,587	)
	Depreciation and amortization		(12,575	)		(22,070	)
	Net Deferred Tax Liabilities		(58,302	)		(68,658	)
	Valuation allowance		802,310			(447,809	)
		$	—		$	—
	A reconciliation between the expected tax expense (benefit) and the effective tax rate for the years ended December 31, 2014 and 2013 are as follows:
		2014			2013
	Statutory federal income tax rate		34	%		34	%
	State taxes, net of federal income tax		5.61	%		5.61	%
	Effect of change in valuation allowance		(21.01	%)		(5.19	%)
	Non-deductible expenses		(18.60	%)		(34.42	%)
			0	%		0	%
	As of December 31, 2014, the Company had a tax net operating loss carry forward of approximately $1,214,000. Any unused portion of this carry forward expires in 2030. Utilization of this loss may be limited in the event of an ownership change pursuant to IRS Section 382.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies
	Employment Agreements
	On June 20, 2011, the Company entered into a two year employment agreement with Mr. Brian Lane, our Chief Executive Officer (Mr. Lane resigned October 27, 2014, see note 6). The agreement, as amended, provided for a base salary of $12,708 per month, annual incentive bonuses based on the Company’s performance in achieving prescribed revenue and earnings before interest and taxes (“EBIT”) targets, and discretionary bonuses.  The amended agreement further provided for a grant of options to acquire 2,000,000 shares of common stock of the Company. Effective June 20, 2013, the Company further amended Mr. Lane’s employment agreement, extending the term through December 31, 2013 and agreed to issue 2,000,000 shares of common stock and cancelled the options. Effective November 1, 2103, the board also agreed to compensate Mr. Lane (Chief Executive Officer) up to $250,000 per annum beginning January 1, 2014, however Mr. Lane and the Company had agreed that he will continue to be paid at his previous annual salary of $152,500. Included in salaries and management fees for the years ended December 31, 2014 and 2013, is $148,315 and $127,954, respectively.
	On November 1, 2013, the Board also agreed to enter into an employment agreement with Mr. Bulat (Chief Innovations Officer) for an annual salary up to $300,000 effective January 1, 2014. The Company and Mr. Bulat agreed to accrue $10,000 per month for the year ended December 31, 2014 and agreed to increase the annual compensation to the full amount at a later date. The corresponding liability is included in accounts payable and accrued expenses, related party as of December 31, 2014.
	On October 27, 2014, Mr. Brian Lane (“Lane”) resigned as CEO of the Company. Mr. Lane remains a member of the Board of Directors of the Company. On October 29, 2014, the Company and Mr. Lane entered into a Resignation and Separation Agreement (the “RSA”). Pursuant to the RSA, the Company has agreed to provide consideration to Mr. Lane of $58,856 in fourteen bi-weekly payments of approximately $4,204. The consideration included wages accrued and unpaid as of October 24, 2014. Mr. Lane’s resignation was not due to any disagreement with the Company, the Board or the Company’s management. As of December 31, 2014, the balance owed Mr. Lane is $37,837 for unpaid salary and severance and is included in accounts payable and accrued expenses related parties.
	On October 30, 2014, the Board of Directors of the Company appointed Mr. Paul Bulat (“Bulat”) as the interim Chief Executive Officer. Mr. Bulat currently also serves as the Chairman of the Board and the Chief Innovations Officer of the Company. There will be no additional compensation due Mr. Bulat and the terms and conditions of his employment agreement as CIO remain in effect (see note 6).
	Consulting Agreements
	On April 15, 2014, the Company entered into a three month Consulting Agreement with a consultant (the “Consultant”) to assist the Company regarding the formation of strategic relationships with existing and new identified technology companies. Additionally, the Consultant worked with the executive management team in developing market strategies and comprehensive video conferencing technology solution offerings including the bundling of these technologies, working with ADOL’s partner on developing licensing packages, creating new sales proposal formats for consultation services and technologies/products, and assisting with the development and placement of products and services. The Company agreed to compensate the Consultant $100 per hour, for a minimum of 40 hours per week, for these services, which may be paid, at the option of the Company, in the form of cash or equity consideration. The parties extended the Agreement through July 31, 2014, at which time the Agreement was terminated. For the year ended December 31, 2014, the Company recorded expenses of $102,500 pursuant to this agreement. On August 18, 2014, the Consultant and the Company entered into a Debt Settlement and Release Agreement, whereby the Company agreed to issue and the Consultant agreed to accept 136,667 shares of the Company’s Series B Preferred Stock as full settlement of the $102,500 due the Consultant.
	Effective June 1, 2013, the Company entered into a consulting agreement with Venture Equity, LLC (“Venture Equity”), whereby Venture Equity will assist the Company in their seeking to become a public company. The Company issued 347,169 shares of common stock and agreed to pay Venture Equity $5,000 per month. On October 7, 2013, the Company appointed Mr. Hollander as the Chief Financial Officer of the Company, and effective on November 1, 2013 (the “Effective date”) agreed to issue Mr. Hollander or his assigns an additional 520,754 shares of common stock of the Company and increased the monthly fee to $8,000. Pursuant to these agreements, Mr. Hollander earned 50% of the additional shares on the nine month anniversary of the Effective Date and earned 50% on the one year anniversary of the Effective Date. As of December 31, 2014, the balance owed Mr. Hollander related to the monthly compensation is $21,000 and is included in accounts payable and accrued expenses related party.
	On June 7, 2013, the Company entered into a consulting agreement with Makena Investment Advisors, LLC. (“Makena”). Pursuant to the one year agreement Makena will assist the Company in its efforts to seek to become a public company, including but not limited to consulting in the preparation of a private placement memorandum, assisting and consulting on the preparation of a registration statement and other consulting services. The Company has agreed to compensate Makena $50,000 and 911,233 shares of the Company’s common stock. Makena began to provide the services in April 2013 and the Company has recorded $37,500 and $12,500 in consulting expenses for the cash portion for the years ended December 31, 2013 and December 31, 2014, respectively, and $455,617 for the equity portion (See note 7) for the year ended December 31, 2014.
	On November 13, 2013, the Company entered into a nine month Placement Agent and Advisory Services Agreement (“PAASA”) with Monarch Bay Securities, LLC (“MBS”). Pursuant to the PAASA, the Company has agreed to pay MBS a retainer of $30,000 and to pay a Success Fee comprised of: a) cash equal to 8% of the gross proceeds raised in a Financing (as defined in the PAASA) including proceeds received from the exercise of any warrants issued in any Financing and b)a warrant to purchase 8% of the total number of shares issued by the Company in connection with the Financing, including the shares issued upon conversion of an exercise of the securities sold in a Financing. The warrant will be issued at an exercise price equal to the purchase price per share sold in the Financing, or in the event that securities convertible into common stock are sold in the Financing, at the conversion price of such securities. The warrant issued to MBS also contains a cashless provision. The Board of Directors of the Company authorized MBS to raise up to Three Million Dollars ($3,000,000) by the sale of Four Million shares (4,000,000) of Series B Convertible Redeemable Preferred Stock, at $0.75 per share. Pursuant to the terms of the PAASA, on May 6, 2014, the Company notified MBS that the Company was terminating the PAASA. MBS has not concluded a Financing and the Company has not incurred any additional expenses.
	Lease Agreements
	The Company utilizes office space in Fairhaven, Massachusetts that is leased from a third party by SLEA, the tenant of the space. There was no formal agreement between the Company and SLEA through December 31, 2014. For the years ended December 31, 2014 and 2013, the Company recorded rent expense of $35,281 (net of a reimbursement from SLEA of $35,281) and $9,558, respectively. The 2013 expense was related to a lease for a satellite office for PDRx (terminated July 2013).
	Litigation
	There are no material proceedings pending or threatened against ADOL. PDRx is a plaintiff in a law suit against HealthBridge Management, Inc. (“Healthbridge”) for non-payment of monies owed for services rendered. HealthBridge has answered the claim with a countersuit against PDRx. The outcome is unknown, legal expenses have been incurred and additional expenses will be forthcoming. The Company does not believe that the disposition or ultimate resolution of existing claims or lawsuits will have a material adverse effect on the business or financial condition of the Company. When and if it appears probable in management's judgment that the Company would incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, liabilities will be recorded in the financial statements and charges will be recorded against earnings.

Going_Concern

Going Concern	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 10 – Going Concern
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of December 31, 2014 the Company had an accumulated deficit of $16,064,010 and a working capital deficit of $983,723. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Management’s Plans
	The Company currently plans to satisfy its cash requirements for the next 12 months though it’s current cash, sales, and raising funds in capital raise transactions and if necessary by borrowing from its officers and directors or companies affiliated with its officers and directors. The Company maintains daily operations and capital needs through the receipts of monthly amounts received pursuant to various license and sub-license agreements, however the Company anticipates that it will need a minimum of $180,000 to continue operations for the next twelve (12) months. ADOL believes it will meet its cash requirements although it has no agreements in place for a capital raise transaction or from any of its officers or directors.